Domain Associates

Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

NPS Pharmaceuticals, Inc. is a biopharmaceutical company based in Bedminster, New Jersey, focused on developing therapeutic products for gastrointestinal and endocrine disorders, particularly rare diseases. The company’s primary offerings include Gattex and Revestive, which are used to treat adult patients with short bowel syndrome (SBS) who rely on parenteral support. Additionally, NPS Pharmaceuticals is advancing Natpara, a bioengineered hormone replacement therapy for hypoparathyroidism, and NPSP795, a calcilytic agent in Phase II clinical trials aimed at treating disorders associated with increased calcium receptor activity. The company operates a global pipeline of innovative therapies, emphasizing patient-centered care for conditions with significant unmet medical needs. Founded in 1986, NPS Pharmaceuticals has established collaborations and licensing agreements with several major pharmaceutical companies to further its mission of providing effective treatments for rare diseases. As of early 2015, it operates as a subsidiary of Shire Pharmaceutical Holdings Ireland Limited.